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Abstract
Background and aims: Efforts to slow or prevent the progressive course of inflammatory bowel 
diseases [IBD] include early and intensive monitoring and treatment of patients at higher risk 
for complications. It is therefore essential to identify high-risk patients – both at diagnosis and 
throughout disease course.
Methods: As a part of an IBD Ahead initiative, we conducted a comprehensive literature review 
to identify predictors of long-term IBD prognosis and generate draft expert summary statements. 
Statements were refined at national meetings of IBD experts in 32 countries and were finalized at 
an international meeting in November 2014.
Results: Patients with Crohn’s disease presenting at a young age or with extensive anatomical 
involvement, deep ulcerations, ileal/ileocolonic involvement, perianal and/or severe rectal 
disease or penetrating/stenosing behaviour should be regarded as high risk for complications. 
Patients with ulcerative colitis presenting at young age, with extensive colitis and frequent 
flare-ups needing steroids or hospitalization present increased risk for colectomy or future 
hospitalization. Smoking status, concurrent primary sclerosing cholangitis and concurrent 
infections may impact the course of disease. Current genetic and serological markers lack 
accuracy for clinical use.
Conclusions: Simple demographic and clinical features can guide the clinician in identifying 
patients at higher risk for disease complications at diagnosis and throughout disease course. 
However, many of these risk factors have been identified retrospectively and lack validation. 
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Appropriately powered prospective studies are required to inform algorithms that can truly predict 
the risk for disease progression in the individual patient.
Keywords:  Complications; Crohn’s disease; disease progression; prognostic factors; risk factors; ulcerative colitis
1. Introduction
Crohn’s disease [CD] and ulcerative colitis [UC] are chronic gas-
trointestinal inflammatory diseases characterized by disabling bowel 
symptoms. Ongoing inflammation leads to progressive bowel dam-
age and complications, often requiring surgery. These diseases are 
associated with significant morbidity, resource utilization and costs 
to society. Furthermore, as these inflammatory bowel diseases [IBD] 
often present early in life, they can compromise education, career 
development and family planning.
The recognition that chronic uncontrolled inflammation in IBD 
ultimately results in poor outcomes has led to a recent paradigm shift 
in treatment, with the belief that early intervention with immunosup-
pressant and biological therapy can prevent disease progression and 
avoid complications.1,2,3,4,5 However, treatment of all patients with bio-
logics and/or combination therapy is economically unsustainable and 
would risk exposing those with an indolent disease course to unneces-
sary risks or side effects of potent therapy. The challenge remains to 
select the patients who will benefit most from early intensive therapy, 
while sparing those who will derive minimal benefit from such treat-
ment.6 The ability to predict specific disease complications such as 
progression of phenotype from inflammatory to penetrating or fibros-
tenotic disease, need for surgery or development of dysplasia or cancer 
would be of particular value, as would being able to identify ‘red flags’ 
that could alert the clinician to an impending flare or relapse.
As part of the IBD Ahead 2014 educational programme, we con-
ducted a comprehensive literature review to identify predictors of 
long-term IBD prognosis and generate draft expert summary state-
ments relating to prognosis. Statements were refined at national 
meetings of IBD experts and were finalized at an international 
meeting in November 2014. Here we present the agreed statements, 
together with a summary of published evidence, to guide clinicians 
on the best use of these predictors in the individual patient.
2. Methods
In February 2014, the Global Steering Committee [GSC] of the IBD 
Ahead 2014 educational programme identified key topics of interest 
or uncertainty in understanding prognostic factors in IBD and devel-
oped clinical questions relating to these topics. Six bibliographical 
fellows [FC, KK, TL, DM, JT and MZ] were nominated by the GSC 
to identify and evaluate the published evidence on prognostic factors 
under the mentorship of JOL, GVA, DR, J-FC and JCL, respectively. 
PubMed, Embase and the Cochrane Library were searched using pre-
defined search strings and limits, and additional searches were con-
ducted by hand as required. Searches were restricted to manuscripts 
published in English after 1993. Abstracts from the following confer-
ences were also searched: European Crohn’s and Colitis Organisation 
Congress 2013, 2014; Digestive Disease Week 2013, 2014; and United 
European Gastroenterology Week 2012, 2013. The bibliographical 
fellows reviewed the evidence and developed summary statements in 
response to the clinical questions, with evidence levels [ELs] assigned 
to each statement based on the University of Oxford Centre for 
Evidence-Based Medicine 2011 criteria [http://www.cebm.net/index.
aspx?o=5653]. In June and July 2014, the literature review subgroup 
[JOL, JCL, GVA] and the programme co-chairs [J-FC, RP] reviewed 
and simplified the statements. National meetings were held in August–
November 2014 in the 32 participating countries to allow participants 
to review, vote and provide their expert opinions and local perspective 
on the statements. Based on this feedback, a set of consolidated state-
ments was generated by the GSC focusing on predictors of long-term 
IBD prognosis. An international meeting was held in November 2014 
with 99 experts from each of the participating countries. Participants 
voted on their level of agreement with each statement using a scale 
of 1 to 9 [where 1=strong disagreement and 9=strong agreement]. If 
≥75% of participants scored within the 7–9 range, then the statement 
was deemed to be agreed upon. If <75% of participants scored within 
this range, the statement was debated and revised, and a second vote 
was taken. Again, if ≥75% of participants scored within the 7–9 range, 
the statement was deemed to be agreed upon. If agreement was not 
reached at this stage, a lack of agreement was noted. The agreed state-
ments and a summary of the supporting evidence are presented here.
3. Results
3.1. Question 1: What are the prognostic factors for 
disease progression – change in disease behaviour [B1 
to B2 and B3], need for therapy escalation, perianal 
disease, bowel damage and disability – in CD?
Summary statements Agreement  
[score 7–9], n/N [%]
1 Ileal disease location [EL2], upper  
gastrointestinal [GI] involvement [EL3] and 
extraintestinal manifestations [EIMs] [EL3] 
are associated with disease progression to 
complicated behaviour* in CD.
66/80 [82%]
2 Younger age and perianal disease at 
diagnosis are associated with a disabling 
course of CD [EL3].
76/83 [91%]
3 Smoking predicts increased need for 
therapy escalation [EL3], progression 
to complicated disease behaviour [EL3], 
need for surgery [EL3] and post-operative 
recurrence in CD [EL3].
80/92 [87%]
4 Endoscopic severity of CD may be as-
sociated with development of penetrating 
complications [EL4].
73/93 [79%]
5 Serological reactivity to certain microbial 
antigens is associated with progression to 
complicated disease behaviour in paedi-
atric and adult-onset CD [EL2]; the risk 
of disease evolution towards complicated 
forms of CD increases with the number of 
antibodies detected in the serum [EL2].
72/91 [79%]
6 Although mutations in some genes (such 
as NOD2 [EL2]) may be associated with 
progression to complicated CD, as yet 
there is no evidence for use of genetic 
markers in clinical practice.
92/98 [94%]
*B2/B3 behaviour.
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CD is an inflammatory disease that may affect the entire GI tract, 
with repeated flares resulting in bowel damage that leads to a com-
plicated disease course and short- and long-term disability. Therapy 
may involve repeated courses of corticosteroids and ultimately sur-
gery.7 Our literature search identified a number of studies evaluat-
ing risk factors for complicated CD outcomes [Table 1]; however, 
interpretation was hindered by the lack of consistent or standard 
definitions of disease progression. Interestingly, we did not find any 
studies documenting risk factors for bowel damage or participation-
related disability.
Two large tertiary-centre studies provided the greatest insight 
into clinical predictors of disability and severe disease in CD.8,9 The 
primary outcome in these studies was disabling disease, defined as a 
requirement for more than two steroid courses, steroid dependence, 
hospitalization for disease flare or complication, disabling chronic 
symptoms for a cumulative time of more than 12 months, or need 
for immunosuppressive therapy, intestinal resection or surgery for 
perianal disease. Variables assessed included gender, ethnicity, age 
at onset, disease location, previous appendectomy, smoking status, 
EIMs, perianal lesions at diagnosis and the need for steroids for 
treating the first flare-up. In the first study, an initial requirement for 
steroids (odds ratio [OR] 3.1; 95% confidence interval [CI] 2.2–4.4), 
age at diagnosis of less than 40  years [OR 2.1; 95% CI 1.3–3.6] 
or the presence of perianal disease at diagnosis [OR 1.8; 95% CI 
1.2–2.8] were independently associated with disabling disease.8 In 
the second study, independent predictors of disabling CD were an 
initial requirement for steroids [OR 1.7; 95% CI 1.0–2.7], perianal 
lesions at diagnosis [OR 2.6; 95% CI 1.4–5.1] and ileocolonic loca-
tion of the disease [OR 1.7; 95% CI 1.1–2.8].9 Another study found 
that older age at diagnosis and the absence of perianal lesions pre-
dicts a milder CD course.10 One of the most important clinical risk 
factors for disease progression is disease location [ileal and ileoco-
lonic vs colonic, rectal involvement, and upper GI involvement].11–15 
In a population-based cohort from North America, disease in the 
terminal ileum, ileocolonic disease and upper GI involvement were 
strongly associated with change in disease behaviour in a multivari-
ate model.16
Other factors that may act as predictors of disease progression 
include smoking, endoscopic disease severity and serological status. 
In several studies in CD patients, active smoking was associated with 
stenosing/fistulizing behaviour,17,18,19 the need for steroids or immu-
nomodulators,20 requirement for surgery21,22 and disease recurrence 
following surgery.23,24 In one study, passive smoking was associated 
with increased need for immunosuppressants and biologics in CD 
patients.25
In the only study identified that specifically assessed the value 
of endoscopic findings in CD, severe endoscopic lesions [defined 
as extensive and deep ulcerations covering more than 10% of the 
mucosal area of at least one segment of the colon] at index colonos-
copy were associated with penetrating complications in CD.26
While the prognostic value of inflammatory markers on CD 
course is limited,27,28,29 results from several independent adult and 
Table 1. Clinical, demographic and endoscopic prognostic predictors in Crohn’s disease [CD] and the associated impact on the disease 
course.
Prognostic factor Impact
Young age at diagnosis •  Disabling CDa [< 40 years]8
•  Need for surgery8,11,24,38,51
•  More frequent L4 disease [paediatric patients]119,120
•  More frequent extensive disease [paediatric patients] 119,120
•  Intestinal failure13
Requirement for steroids at diagnosis •  Disabling CDa8
Complicated behaviour [B2 and/or B3] •  Surgery9,38,42,48
•  Hospitalization54,86
Ileal disease[L1] and ileocolonic disease [L3] •  Surgery28,38,45
•  Disabling CDa8
•  Complicated behaviourb16
•  Disease behaviour progression16
•  Time to hospitalization54,86
Colonic CD •  Inflammatory phenotype51
•  Milder course [protective from hospitalization and surgery]22,38
•  Permanent stoma [distal disease, severe rectal disease, rectal resection]57
Upper GI extent [L4] •  Complicated behaviour15
•  Hospitalization81
•  Multiple surgeries15
Perianal disease •  Disabling CD*8
•  Permanent stoma [refractory perianal disease, anal canal stricture, complex fistulizing disease]57
Deep ulcerations at index colonoscopy •  Surgery26
•  Penetrating complications26
Smoking •  Complicated CD [disease progression]75
•  Higher therapeutic requirements20
•  Risk for first surgery [conflicting evidence]22,48
Positive antimicrobial markers •   Risk of complicated phenotype and surgery [increasing with higher number of positive antibodies 
and higher titres]43
NOD2 mutations •  Ileal disease37
•  Risk for surgery33
aAs defined by Beaugerie.8
bB2 and/or B3.
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paediatric cohorts have indicated that circulating antibodies against 
bacterial antigens are associated with complicated CD and evolu-
tion towards stricturing or penetrating behaviour.30,31 Interestingly, a 
direct correlation was observed between the magnitude of immune 
response to microbial antigens and frequency of penetrating/stenos-
ing disease in children. Additionally, paediatric CD patients who 
were positive for one or more immune response progressed to pen-
etrating or stricturing disease sooner after diagnosis compared with 
those negative for all immune responses.31
An association between mutations in the NOD2 gene and com-
plicated disease phenotype has been suggested in several independent 
cohorts32,33 and a meta-analysis.34 However, the low effect size of other 
CD-associated genetic polymorphisms means that a very large sample 
size is required to make true associations between genotype and phe-
notype. Current studies have lacked power to establish a true associa-
tion and do not adequately take into account the effects of age, disease 
location, smoking and other variables on phenotype. Moreover, several 
studies have reported that NOD2 mutations are specifically associated 
with stricturing ileal disease, which almost certainly accounts for the 
reported association with increased rates of surgery.35,36 Indeed, this 
association disappears if the data are corrected for disease location.37
3.2. Question 2: What are the prognostic factors for 
surgery or multiple surgeries in CD?
The cumulative probability of surgery in CD has been evaluated in 
several population-based cohorts.21,38,39,40 A number of clinical risk fac-
tors have been associated with an increased need for surgery [Table 1]. 
In adult patients, younger age at diagnosis is a prognostic factor for 
surgery.38,39,41 Within the paediatric population, available data suggest 
an opposite trend, however, with younger age at diagnosis associated 
with a decreased risk of surgery.42,43,44 One potential explanation for 
this observation is that younger paediatric patients present more com-
monly with isolated colonic disease,42 which has been repeatedly asso-
ciated with lower surgical rates [see below].
Disease location is among the most important prognostic factors for 
surgery in CD, and should actively be incorporated into clinical deci-
sion-making. Disease located in the small bowel [ileal/ileocolonic dis-
ease] has been consistently identified as an independent risk factor for 
surgery in adult populations,21,38,45,46,47,48 possibly because small bowel 
disease is more frequently associated with penetrating and stenosing 
behaviour.22 Disease located in the jejunum and upper GI tract [L4] 
is also indicative of higher surgical risk for similar reasons,11,12,13,14,15,49 
while colonic disease [L2] is protective against major surgery.22,42,49,50,51
Penetrating and stricturing disease at diagnosis is possibly the 
most important independent factor associated with the need for sur-
gery.21,38,42,48 Furthermore, patients who have surgery for penetrating 
complications have a higher likelihood of being re-operated on and a 
shorter time to second surgery.15,52 Extensive and deep ulcerations on 
index colonoscopy have been shown in a retrospective study to rep-
resent an independent risk factor for surgery, in patients with colonic 
disease.26
A large systematic review and meta-analysis found that the risk 
of any CD surgery was increased by 58% if any NOD2 mutation 
was present, with a pooled sensitivity of 41% and a specificity of 
74%.34 A meta-analysis of seven cohort studies and four case-control 
studies showed an association between ASCA-positive status and 
surgery risk [OR 1.64; 95% CI 1.37–1.95].53 In addition, greater 
immune responses to anti-Cbir1, anti-ompC, ASCA and perinuclear 
anti-neutrophil cytoplasmic antibody [p-ANCA] were shown to be 
predictive of surgery in a paediatric population.43 The increased 
risk of surgery associated with these genetic and serological mark-
ers probably also reflects their association with ileal and ileocolonic 
disease and complicated disease behaviour.
3.3. Question 3: What are the prognostic factors for 
hospitalization in CD?
Hospitalization is generally regarded as a marker of high dis-
ease activity or severity in CD. However, our review of the literature 
revealed that very few studies have assessed predictive factors of hospi-
talization in patients with CD [Table 1]. Generally, risk factors associ-
ated with disease progression and risk for surgery are also associated 
with higher likelihood of hospitalization because they are markers of 
disease aggressiveness and severity. In a population-based study from 
Olmsted County, MN, USA, factors associated with time to first hos-
pitalization included ileocolonic disease (hazard ratio [HR] 3.3; 95% 
CI 1.8–5.8), small bowel disease [HR 3.4; 95% CI 1.9–6.1] and gas-
troduodenal disease [HR 4.0; 95% CI 1.2–13.8] as opposed to coli-
tis.21 Compared with non-penetrating and non-stricturing disease, pen-
etrating disease also increased the risk of first major abdominal surgery 
[HR 2.7; 95% CI 1.1–6.7].21 Similar findings have been reported in 
other cohorts.49,51,54
3.4. Question 4: What are the prognostic factors for 
intestinal failure or permanent stoma in CD?
Summary statements Agreement  
[score 7–9], n/N [%]
1 Younger age at diagnosis [adults <40 years] 
increases risk of surgery [EL2]; in paediatric 
patients, younger children have lower risk 
for surgical resection [EL3].
85/96 [89%]
2 Disease located in the small bowel carries a 
higher risk for surgery than isolated colonic 
disease [EL2].
86/90 [96%]
3 Penetrating and stricturing phenotypes at 
diagnosis are independent risk factors for 
surgery [EL2].
92/99 [93%]
4 Extensive and deep ulcers at colonoscopy 
in patients with colonic CD may predict the 
need for surgery [EL4].
79/88 [90%]
5 NOD2/CARD15 polymorphisms and/or 
anti-Saccharomyces cerevisiae antibodies 
[ASCA]-positive status may be associated 
with an increased risk of surgery [EL2].
72/82 [90%]
Summary statement Agreement  
[score 7–9], n/N [%]
1 CD involving the rectal, perianal and /or 
perineal regions, particularly stricturing and 
complex fistulizing disease, is a risk factor 
for permanent stoma [EL3].
62/71 [88%]
Summary statement Agreement  
[score 7–9], n/N [%]
1 Penetrating and stricturing phenotypes  
predict hospitalization and re-hospitalization 
[EL2].
68/74 [92%]
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Permanent stoma may be a therapeutic necessity in patients with refrac-
tory rectal or perianal CD and severe Cohn’s proctocolitis. Identification 
of risk factors at an earlier stage of disease may guide more intensive medi-
cal intervention, preventing the development of strictures and fistulae that 
ultimately result in the need for irreversible surgery. In our review of the 
evidence [primarily in patients with perianal and/or colonic CD], the most 
frequent factors independently associated with a permanent stoma were: 
complex perianal fistulae,55,56 anal-canal stricture,57 perineum involvement 
and perineal granulomas,58 perianal sepsis,59 faecal incontinence,55 colonic 
CD59 and distal colonic involvement.57,60 Additionally, patients undergo-
ing rectal resection or temporary faecal diversion for perianal disease 
control have a higher rate of permanent faecal diversion.55,61 Patients with 
permanent stoma have typically experienced a greater number of previ-
ous abdominal surgeries than those without a permanent stoma.55,59 It is 
important to acknowledge that the likelihood of successful stoma reversal 
after temporary diversion for control of perianal sepsis or disease is low.
Intestinal failure is a rare complication of CD, with a lack of consist-
ent risk factors reported in the literature. Nevertheless, bowel-preserving 
strategies, such as strictureplasty or stricture balloon dilation, should be 
used whenever possible to prevent intestinal failure.
3.5. Question 5: What are the prognostic factors for 
proximal disease extension in UC?
UC is a dynamic disease, with up to 50% of patients progress-
ing from limited forms of disease [proctitis, left-sided colitis] to 
more extensive forms of colitis [extensive colitis, pancolitis].62,63 The 
extent of colitis is clinically relevant, as extensive colitis is associated 
with higher hospitalization rates, need for corticosteroids, greater 
likelihood of surgery, and increased risk of progression to dysplasia 
and colorectal cancer [CRC]. The ability to identify patients who are 
likely to experience disease extension would allow close monitor-
ing and tight control, and perhaps more intensive treatment. It is 
important to note that most studies on this topic address association 
of potential risk factors with extensive colitis, rather than predict-
ing proximal extension of disease, and do not allow assessment of 
whether the same factors that cause proximal disease extension are 
also predictive of extensive disease from the onset. This analysis was 
limited to studies that specifically evaluated risk factors for proxi-
mal disease extension [Table 2]. In a paediatric cohort with UC, a 
delay in diagnosis of more than 6 months and a family history of 
IBD were associated with increased risk of proximal disease exten-
sion [OR 5.0; 95% CI 1.2–21.5 and OR 11.8; 95% CI 1.3–111.3, 
respectively].64 In an adult cohort, independent factors associated 
with disease proximal extension were younger age at diagnosis [HR 
0.98, 95% CI 0.96–0.999] and the presence of PSC [HR 12.83, 95% 
CI 1.36–121.10].65 More than three relapses in one year, a require-
ment for systemic steroid or immunosuppressive treatment and 
non-smoking were associated with risk of proximal extension in a 
retrospective cohort study of adults with UC.66 Increased severity of 
disease and use of corticosteroids upon diagnosis were significantly 
associated with proximal disease extension in adults with ulcerative 
proctitis.67
3.6. Question 6: What are the prognostic factors for 
acute severe UC?
Table 2. Clinical, demographic and endoscopic prognostic predic-
tors in ulcerative colitis [UC] and the associated impact on disease 
course.
Prognostic factor Impact
Young age at diagnosis More extensive disease [paediatric 
UC]80
Colectomy64
Proximal disease extension64
Acute severe UC68
Colorectal neoplasia85
Family history Proximal disease extension [family 
history of IBD]64
Colorectal neoplasia [family history 
of CRC]103
Refractory proctitis  
[>3 relapses per year]
Proximal disease extension 66
Male sex Colectomy78
Extensive colitis Colectomy68
Acute severe UC68
Hospitalization 82
Colorectal neoplasia89
High histological  
inflammation score
Colorectal neoplasia101
Disease duration >10 years Colorectal neoplasia85,121
Colectomy24
Steroid dependence/ 
resistance
Colectomy69
Hospitalization122
Smoking Less need for hospitalization72
Proximal disease extension [protec-
tive]66
Protective from colectomy73
Concurrent infection  
[cytomegalovirus or  
Clostridium difficile]
Flare and hospitalization76,77
Primary sclerosing  
cholangitis
Colectomy84
Proximal disease extension65
Colorectal cancer71
Protective for hospitalization70
Summary statement Agreement  
[score 7–9], n/N [%]
1 Clinical factors (delay in diagnosis of 
>6 months [EL3], family history of IBD 
[EL3], young age at diagnosis and disease 
severity), need for steroids at diagnosis, poor 
response to therapy [>3 relapses per year] 
and concurrent primary sclerosing cholangitis 
[PSC] may be associated with increased risk 
of proximal disease extension in UC [EL4].
53/70 [76%]
Summary statements Agreement  
[score 7–9], n/N [%]
1 Extensive disease [EL2], younger age at 
diagnosis [EL3] and shorter duration of 
disease [EL2] are clinical risk factors for 
acute severe UC.
73/83 [88%]
2 PSC reduces the risk of hospitalization for 
UC flare [EL2].
34/44 [78%]
3 Active smokers have a reduced risk of 
hospitalization for UC flare [EL2].
71/86 [83%]
4 Extensive disease and concurrent infection 
with cytomegalovirus [EL3] or Clostridium 
difficile [EL4] are risk factors for hospitali-
zation for UC flare.
76/85 [89%]
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Acute severe UC is a medical emergency that requires intensive 
medical therapy or colectomy; however, robust prognostic factors 
for this event have not been established [Table 2]. In a retrospec-
tive analysis of a cohort of 750 patients in the UK diagnosed with 
UC from 1996 to 2001, acute severe UC occurred more frequently 
in patients with more extensive disease, a younger age at diagnosis 
and a shorter duration of disease.68 More recently, Cesarini et  al. 
have shown that the likelihood of developing acute severe UC within 
3 years of diagnosis was increased in patients with extensive coli-
tis [E3 from Montreal classification] who presented with C-reactive 
protein [CRP] >10 mg/l and low haemoglobin [<13.5 g/dl for men 
or 12.1 g/dl for women].69 Data from this single-centre study require 
validation in external cohorts.
In the absence of studies evaluating acute severe UC as a defini-
tive endpoint, hospitalization due to UC flares may act as a surrogate 
marker. A concurrent diagnosis of PSC may be a protective factor for 
hospitalization in UC patients,70 which is in accordance with studies 
suggesting that PSC carries a milder course of colonic activity in UC 
patients.71 Smoking has also been associated with a lower hospitali-
zation rate in UC;72 conversely, quitting smoking increases the risk of 
hospitalization.73,74 Finally, extensive colitis,75 cytomegalovirus infec-
tion76 and C. difficile infection77 are risk factors for hospitalization 
for UC flare.
3.7. Question 7: What are the prognostic factors for 
colectomy in UC?
In patients with UC, colectomy is undertaken in the emergency set-
ting [typically for complications of fulminant colitis], in hospitalized 
patients who are non-responsive to maximal medical therapy and as 
elective treatment in patients who have persistent symptoms despite 
medical therapy, dysplasia or CRC. We recognize that it is important to 
distinguish prognostic factors according to colectomy context [Table 2].
In an analysis of the University of Manitoba IBD Epidemiology 
Database, predictors of early colectomy [≤90 days from diagnosis 
date] included male sex (HR 2.63; [corrected] 95% CI 1.58–4.36) 
and being initially diagnosed during hospitalization [HR 12.46; 95% 
CI 7.40–21.0].78 A review of the literature found that disease extent, 
particularly extensive disease24,79 and pancolitis,80 may predict sub-
sequent colectomy. Longer disease duration was also identified as 
a risk factor, both in adults24,81 and in children.80 However, caution 
is needed when interpreting the evidence as the data are cumula-
tive and are confounded by the differences in follow-up duration. 
Patients who are hospitalized at UC diagnosis78,82 or require recur-
rent hospitalization for UC management82 should be carefully moni-
tored for colectomy indicators. While the presence of PSC reduces 
the risk of hospitalization for UC [discussed previously], it is also 
a risk factor for colectomy, primarily due to the associated risk of 
colorectal neoplasia.83 There is limited evidence that active smoking 
is protective against colectomy84 and smoking cessation in patients 
with established UC has not been shown conclusively to influence 
the rate of colectomy.73
3.8. Question 8: What are the prognostic factors for 
dysplasia and CRC in IBD?
Early intervention with immunosuppressive or biological therapies 
may have contributed to an overall decline in the incidence of CRC 
in patients with IBD, although it is evident that some subgroups of 
patients with UC remain at increased risk of CRC.85 In patients with 
IBD, independent risk factors for the development of CRC or high-
grade dysplasia include longer duration of IBD85,86,87,88 and greater 
extent of colonic involvement at diagnosis.86,87,89 The excess risk 
becomes significant 7–10  years after diagnosis in the general IBD 
population90 although it is immediately seen in patients with PSC.85 
In UC, disease extent is also a predictor for CRC development, with 
increased risk in patients with pancolitis compared with left-sided or 
distal colitis.87,89,91,92 A number of studies have shown that the con-
current presence of PSC is a strong risk factor for dysplasia or CRC 
development,85,93,94,95,96,97 warranting special surveillance protocols. 
Furthermore, when assessing for site of cancer development, PSC 
was a predictor of cancer proximal to the splenic flexure.96 In a study 
in patients with colonic CD, the presence of PSC was weakly associ-
ated with the development of dysplasia or CRC.98
Two referral centre studies have demonstrated an association 
between histological inflammation score and the development of dys-
plasia or CRC in patients with UC,99,100 and one case-control study 
found that every 1-unit increase in histological score independently 
increased the odds of colorectal neoplasia by a factor of 4.69 [95% 
CI 2.10–10.48].101 The possible relationship between elevated CRP 
or erythrocyte sedimentation rate and CRC102 may also support the 
association between poorly controlled inflammation and cancer risk.
Among IBD patients with a first-degree relative with CRC, the 
relative risk [RR] of developing CRC was increased [RR 2.5; 95% 
CI 1.4–4.4] and remained elevated for both UC [RR 2.0; 95% CI 
1.0–9.4] and CD [RR 3.7; 95% CI 1.4–9.4].103 Furthermore, the 
RR was higher for those with a first-degree relative diagnosed with 
CRC before age 50 [RR 9.2; 95% CI 3.8–23]. Male sex is inde-
pendently associated with the development of CRC or high-grade 
dysplasia.86,100,104 While total disease duration is associated with the 
Summary statements Agreement  
[score 7–9], n/N [%]
1 Duration of disease, extent of disease and 
PSC are associated with the development 
of CRC in colonic IBD [EL2].
80/84 [95%]
2 Persistent histological activity is associated 
with the development of dysplasia and 
CRC in UC [EL3].
76/81 [94%]
3 Family history of a first-degree relative 
with sporadic CRC is associated with the 
development of CRC in IBD [EL3].
72/84 [86%]
4 Male sex [EL2] is associated with the 
development of CRC in IBD; older age 
at diagnosis [EL3] is associated with a 
decreased time interval to CRC develop-
ment in IBD.
61/78 [78%]
Summary statements Agreement  
[score 7–9], n/N [%]
1 Male sex [EL3] and early disease onset [EL3] 
are associated with colectomy in adults.
62/77 [81%]
2 Disease characteristics (extensive disease 
[EL3], disease of >10 years’ duration [EL3] 
and severe disease at index admission [EL3]), 
presence of PSC [EL2] and frequent hospitali-
zation for severe UC flares [EL3] are clinical 
predictors for [all-cause] colectomy in UC.
72/82 [88%]
3 Active smoking reduces colectomy rates [EL2]. 64/83 [77%]
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development of CRC, older age at diagnosis has been associated with 
shorter time to CRC onset.86,89,93,105,106
3.9. Question 9: What are the prognostic factors for 
death in IBD?
There are few identified predictor factors for mortality in IBD. A meta-
analysis of 10 studies reported standardized mortality ratios [SMRs] 
in UC with a range from 0.7 to 1.4. The pooled ratio did not demon-
strate an overall risk of dying that was different from the background 
population [pooled SMR 1.1; 95% CI 0.1–1.2].107 A  similar meta-
analysis of nine studies in CD reported a range of SMRs from 0.72 
to 3.2, with a pooled SMR of 1.39 [95% CI 1.30–1.49] reflecting an 
increased overall mortality in patients with CD compared with the 
background population.108 The risk of death after adjustment for sex 
and smoking was compared in a large population cohort study includ-
ing 16 550 patients with IBD and 82 917 matched controls; among 
patients with UC, those aged 40–59 years had the greatest increase 
in risk of death [HR 1.79; 95% CI 1.42–2.27], while in patients with 
CD, those aged 20–39 years had the largest statistically significant risk 
for death [HR 3.82; 95% CI 2.17–6.75].109 One cohort study found 
that age at diagnosis and male gender were independently associated 
with mortality in patients with UC; in patients with CD, only age at 
diagnosis was statistically significant.110 Another study found an inde-
pendent association between PSC and mortality in IBD patients.111
4. Implications for practice
Stratifying patients and individualizing therapy in IBD should be an 
ongoing process. It is important for treating physicians and patients 
to understand which factors are associated with different outcomes 
as this may influence important therapeutic decisions. Evaluating 
these factors should arguably be the first step in stratifying patients 
into low-risk or high-risk groups and should drive treatment target 
discussions. It is equally important to actively pursue and document 
resolution of inflammation and adjust therapy accordingly [treat to 
target], offering the clinician the opportunity to improve patient out-
comes at every stage of the disease process.112 Postponing adequate 
therapy in patients with aggressive disease may result in disease pro-
gression and complications; however, treating all patients intensively 
may lead to over-treatment and expose some patients to unneces-
sary risks of immunosuppression.113 Therefore, it is important to be 
aware of the risk factors associated with specific complications and 
to use these to tailor therapy. Briefly, patients with CD presenting 
with a young age at diagnosis, extensive anatomical involvement, 
deep ulcerations at endoscopy, ileal or ileocolonic involvement, peri-
anal disease and/or severe rectal disease and penetrating or stenosing 
behaviour should be regarded as those with the highest probability 
of developing complications and therefore merit intensive therapy 
and close follow-up.114 Patients with UC presenting at young age at 
diagnosis, with extensive colitis and frequent flare-ups needing ster-
oids or hospitalization bear a higher risk of colectomy. Concurrent 
presence of PSC, smoking status and superimposed infections may 
impact the course and activity of UC; therefore, these are clinical risk 
factors needing attention from the clinician.
5. Future directions
The use of prognostic factors to guide IBD management is an evolving 
field. We must be mindful that most of the currently available prog-
nostic factors in IBD are clinical and lack precision. Furthermore, 
many of these risk factors have been identified retrospectively and 
have yet to be validated; appropriately powered prospective stud-
ies are still required to inform algorithms that can truly predict the 
risk for disease progression in the individual patient. While use of 
serological and genetic markers in prognostication has been ham-
pered by lack of sensitivity and lack of wide availability, these are of 
increasing clinical interest. Indeed, composite scores incorporating 
clinical information and molecular profiling, and considering harder 
endpoints such as bowel damage115,116 and disability,117 will hope-
fully allow us to better personalize therapy in the future, both at 
diagnosis and throughout the disease course.118
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